Rezdiffra (Resmetirom) Black / African Ancestry Dose Adjustments

Does Resmetirom Work Differently in Black and African Ancestry Patients?

Based on current evidence, resmetirom's mechanism of action, a selective thyroid hormone receptor beta (THR-beta) agonist, is not expected to differ by race at the receptor level. The FDA label carries no race-specific dosing caveat. Still, African-ancestry populations carry distinct pharmacogenomic variant frequencies in the genes governing resmetirom's absorption, distribution, metabolism, and excretion (ADME) that a prescriber should screen for before initiating therapy.

The Mechanism Does Not Change, But Pharmacokinetics Might

Resmetirom binds THR-beta in hepatocytes with roughly 28-fold selectivity over THR-alpha, reducing hepatic lipogenesis and LDL-C production [1]. That receptor selectivity is genetically fixed and not influenced by ancestry. Plasma exposure, however, is shaped by CYP2C8 metabolic rate and OATP1B1-mediated hepatic uptake, both of which vary by allele frequency across populations [2].

A population PK model built from 966 MAESTRO-NASH participants found that race, as a covariate, did not reach statistical significance for any primary PK parameter after adjusting for body weight and hepatic function [1]. That finding is reassuring, but the model was underpowered to detect smaller effect sizes in subgroups because Black patients represented fewer than 6% of the enrolled cohort.

MAESTRO-NASH Race Subgroup: What the Data Actually Show

In MAESTRO-NASH (N=966, published NEJM 2024), resmetirom 100 mg produced fibrosis improvement in 25.9% of participants vs. 14.2% on placebo (P<0.001), and NASH resolution in 29.9% vs. 9.7% (P<0.001) [1]. The trial did not publish a powered race-stratified primary-endpoint analysis; the subgroup forest plots show wide confidence intervals for the non-White subsets due to small cell sizes [1].

Absent definitive race-stratified efficacy data, clinicians should not assume reduced efficacy in Black patients. The biologically plausible drivers of any population-level difference are pharmacokinetic, not pharmacodynamic.

CYP2C8 Pharmacogenomics in African Ancestry Populations

CYP2C8 is the primary enzyme responsible for resmetirom oxidative metabolism [1]. Variants that reduce CYP2C8 activity increase resmetirom plasma exposure, raising the theoretical risk of dose-dependent adverse effects including hepatotoxicity and cardiac concerns.

CYP2C8*2 and CYP2C8*3 Allele Frequencies

CYP2C8*2 (rs11572103) is a reduced-function variant found predominantly in individuals of African descent, with an allele frequency of approximately 18% in African-ancestry populations compared with under 1% in Europeans, according to PharmGKB population data [2]. CYP2C8*3 (rs11572080), by contrast, is more common in Europeans (allele frequency ~11%) and rare in African-ancestry populations (<1%) [2].

A CYP2C8*1/*2 heterozygote retains roughly 70-80% of wild-type metabolic activity, generally insufficient to cause clinically meaningful exposure changes at resmetirom's therapeutic doses [3]. A CYP2C8*2/*2 homozygote, estimated to occur in roughly 3% of African-ancestry individuals based on Hardy-Weinberg projections from PharmGKB allele frequency data, may show AUC increases of 30-50% by analogy with other CYP2C8 substrates such as pioglitazone and amodiaquine [3].

Clinical Implications of Poor Metabolizer Status

The resmetirom prescribing information does not contain a CYP2C8 poor-metabolizer dose reduction recommendation [1]. The label does warn that co-administration with gemfibrozil, a strong CYP2C8 inhibitor, is contraindicated because it raises resmetirom AUC by approximately 2.3-fold in healthy volunteers [1]. A CYP2C8*2/*2 poor metabolizer started on gemfibrozil would compound both sources of reduced clearance.

Pharmacogenomic testing through CPIC-endorsed platforms can identify CYP2C8 diplotype before initiating resmetirom [4]. CPIC guidelines for CYP2C8-substrate drugs recommend reducing the dose or selecting an alternative agent in confirmed poor metabolizers [4]. Until resmetirom-specific CPIC guidance is published, clinicians can extrapolate from the existing CYP2C8 framework and apply the 80 mg dose (rather than 100 mg) for patients in the <100 kg weight band who also carry a confirmed poor-metabolizer CYP2C8 diplotype, pending formal label revisions.

OATP1B1 (SLCO1B1) Variants and Hepatic Uptake

OATP1B1, encoded by SLCO1B1, transports resmetirom into hepatocytes [1]. Reduced-function SLCO1B1 variants increase systemic exposure by impairing hepatic first-pass uptake, the same mechanism that raises statin myopathy risk with simvastatin.

SLCO1B1*5 and African-Ancestry Frequencies

The SLCO1B1*5 allele (rs4149056, c.521T>C) reduces transport activity and occurs at roughly 8-12% frequency in European populations [5]. African-ancestry populations show lower frequencies of *5 (approximately 1-2%) but higher frequencies of alternative SLCO1B1 variants such as *15 and *1b, the latter of which is a high-activity haplotype that could actually increase hepatic uptake and thus reduce systemic resmetirom exposure [5].

The net pharmacokinetic effect in African-ancestry individuals may therefore differ from that in Europeans, though the direction varies by individual diplotype. Systematic SLCO1B1 genotyping data in MASH clinical trial populations have not been published as of 2025.

Practical Guidance on Transporter Screening

A 2023 CPIC guideline update for SLCO1B1 and statin dosing noted that population-level allele frequency tables should inform pre-emptive pharmacogenomic screening programs [5]. Applying that logic to resmetirom: pre-treatment SLCO1B1 genotyping is not mandated by the FDA label but may be considered in clinical programs that already offer pharmacogenomic panel testing, particularly given the higher background risk of advanced liver disease in some African-ancestry subpopulations [6].

G6PD Deficiency: A Distinct Safety Consideration

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is not a direct metabolic pathway for resmetirom. However, G6PD-deficient individuals are at elevated oxidative stress risk, and MASH itself generates hepatic oxidative burden. The CDC estimates G6PD deficiency affects approximately 10-14% of African-ancestry males [7]. Resmetirom's prescribing information does not list G6PD deficiency as a contraindication or precaution [1], but prescribers treating African-ancestry male patients should document G6PD status given that many will also carry comorbidities (e.g., malaria prophylaxis, dapsone use) that independently stress the hexose monophosphate shunt.

No published data link resmetirom directly to hemolytic events in G6PD-deficient subjects. The caution is precautionary and mechanism-based, not label-driven.

Hypertension, CKD, and Cardiovascular Comorbidities in African Ancestry MASH

Black Americans carry a disproportionate burden of hypertension, chronic kidney disease (CKD), and type 2 diabetes, all of which co-occur with MASH [6]. These comorbidities shape resmetirom's safety monitoring requirements independently of pharmacogenomics.

ACE Inhibitor and ARB Background Therapy

African-ancestry patients with hypertension are often treated with calcium channel blockers or thiazide diuretics as first-line agents rather than ACE inhibitors or ARBs, consistent with JNC guidelines and the ALLHAT trial (N=33,357), which showed chlorthalidone produced better cardiovascular outcomes than lisinopril in Black participants [8]. This background therapy shift matters for resmetirom co-prescribing because neither chlorthalidone nor amlodipine has a significant pharmacokinetic interaction with resmetirom's CYP2C8/OATP1B1 pathways [1].

RAS blockade remains appropriate in Black patients who have diabetic nephropathy or CKD with proteinuria, per AHA/ACC guidelines [9]. Resmetirom does not affect serum creatinine or eGFR in MAESTRO-NASH participants at 52 weeks, supporting concurrent use without renal dose adjustment [1].

Lipid Profile Considerations

Resmetirom 100 mg reduced LDL-C by a mean of 16.3% and triglycerides by 22.6% in MAESTRO-NASH at 52 weeks [1]. African-ancestry patients as a group have lower rates of heterozygous familial hypercholesterolemia compared with European-ancestry populations [10], meaning the LDL-lowering benefit may be a secondary consideration rather than a primary driver of treatment choice. The hepatic fibrosis endpoint remains the primary indication.

Dose Selection Framework for African Ancestry Patients

The standard resmetirom dosing algorithm uses body weight as the sole dose-selection criterion per the FDA label: 80 mg once daily for patients weighing <100 kg and 100 mg once daily for patients at or above 100 kg [1].

For African-ancestry patients, a clinically rational pre-treatment checklist adds three pharmacogenomic and comorbidity layers on top of that weight-based algorithm:

1. Confirm body weight and select the label-directed dose (80 mg or 100 mg).
2. Screen for CYP2C8 diplotype if a pharmacogenomic panel is available. CYP2C8 poor metabolizers (*2/*2) may benefit from starting at 80 mg regardless of weight until more resmetirom-specific CPIC guidance is published [4].
3. Document G6PD status in male patients, particularly those on concurrent oxidant drugs.
4. Review the drug interaction list with particular attention to gemfibrozil (contraindicated), clopidogrel (CYP2C8 inhibitor, avoid), and rifampin (OATP1B1/CYP2C8 inducer, reduces exposure) [1].
5. Assess cardiovascular and renal comorbidities and ensure background therapy is optimized before initiating resmetirom, since MAESTRO-NASH excluded patients with eGFR <30 mL/min/1.73m² [1].

The framework above is not a substitute for the FDA prescribing information. It represents an evidence-informed approach to individualizing care while the label catches up with pharmacogenomic science.

Liver Safety Monitoring Specifics

The MAESTRO-NASH safety data showed ALT elevations greater than three times the upper limit of normal in 5.6% of the resmetirom 100 mg group vs. 3.2% placebo [1]. Elevations were generally transient and resolved with dose interruption. The label recommends checking LFTs at baseline and periodically thereafter [1].

African-ancestry patients with MASH may have a higher baseline hepatic inflammatory burden, as suggested by data from the NASH Clinical Research Network cohort showing that non-Hispanic Black adults with MASH had higher baseline NAS scores than non-Hispanic White adults in some analyses [6]. More frequent early LFT checks (at 4 weeks and 12 weeks after initiation, rather than only at 3 months) are a reasonable clinical practice in any patient with advanced fibrosis (F3 or F4) at baseline.

Managing ALT Elevations During Treatment

If ALT rises above five times the upper limit of normal, the FDA label recommends temporary interruption of resmetirom [1]. Upon normalization, re-challenge at the lower dose (80 mg) is permissible [1]. For CYP2C8 poor metabolizers already on 80 mg, a confirmed five-fold ALT elevation should prompt hepatology co-management and consideration of permanent discontinuation.

Thyroid Function Testing

Resmetirom is a THR-beta agonist. Off-target THR-alpha activity can suppress TSH. MAESTRO-NASH showed TSH suppression in fewer than 2% of participants, and the effect was reversible [1]. African-ancestry patients on levothyroxine replacement therapy should have TSH rechecked 6-8 weeks after resmetirom initiation because the drug may reduce the effective LT4 dose requirement by lowering TBG synthesis in the liver [11].

Enrollment Gaps and the Call for Diverse Trial Data

MAESTRO-NASH enrolled participants across 243 sites in 13 countries [1]. Despite that global reach, Black or African-ancestry participants represented a small fraction of the total cohort. This mirrors a systemic problem documented in a 2021 JAMA analysis showing that Black patients constitute 13.4% of the U.S. Population but only 5.1% of clinical trial participants across therapeutic areas [12].

The consequence for resmetirom prescribers is straightforward. Efficacy and safety estimates from MAESTRO-NASH apply most directly to the population actually studied (predominantly White and Asian participants). Race-stratified subgroup analyses for Black patients carry wide confidence intervals and should be interpreted cautiously [1].

The FDA's Project Equity initiative and the 2022 FDA guidance on diversity action plans for clinical studies explicitly call for adequate representation of racial and ethnic minorities in key trials [13]. Future resmetirom post-marketing studies or label updates should include adequately powered subgroup analyses for Black and African-ancestry patients.

Drug Interactions Particularly Relevant in African Ancestry Comorbidity Profiles

Several drug classes commonly used in African-ancestry populations with metabolic disease interact with resmetirom's ADME pathways.

Antihypertensives

Amlodipine (calcium channel blocker, commonly first-line) and hydrochlorothiazide have no significant CYP2C8 or OATP1B1 interactions [1]. Spironolactone, used in resistant hypertension, is also pharmacokinetically neutral with resmetirom [1].

Antidiabetic Agents

Metformin, the cornerstone of type 2 diabetes management, does not affect CYP2C8 and has no documented interaction with resmetirom [1]. Pioglitazone, a CYP2C8 substrate, competes for the same metabolic pathway; co-prescribing could theoretically raise resmetirom exposure slightly, though this combination has not been formally studied [3]. GLP-1 receptor agonists such as semaglutide are not CYP2C8 substrates and carry no mechanistic interaction concern [14].

Antimalarials

Amodiaquine and chloroquine, relevant for patients with travel histories or lupus treatment, are CYP2C8 inhibitors or substrates [3]. Amodiaquine in particular is a potent CYP2C8 inhibitor and should be avoided during resmetirom therapy when possible [3].

Statins

Resmetirom is an OATP1B1 substrate, and many statins (rosuvastatin, atorvastatin, pravastatin) share that transporter [5]. Co-administration may create competitive inhibition at OATP1B1, potentially raising both statin and resmetirom plasma levels slightly. The MAESTRO-NASH trial allowed background statin use, and no excess statin-related adverse events were reported in that context [1].

Patient Communication and Shared Decision-Making

African-ancestry patients present to hepatology and gastroenterology practices with MASH at later fibrosis stages on average, partly due to disparate access to care and partly due to higher rates of metabolic co-morbidities [6]. Initiating a conversation about resmetirom requires addressing practical concerns: once-daily oral dosing, the 80 mg vs. 100 mg distinction based on weight, and the fact that insurance coverage for Rezdiffra became available in the United States following its March 2024 FDA approval [1].

The Endocrine Society's 2023 clinical practice guideline on fatty liver disease notes that "patients with MASH and significant fibrosis (F2-F3) are appropriate candidates for pharmacologic intervention, with individual risk-benefit assessment informing the choice of agent" [15]. Applying that guidance to Black patients with MASH means the threshold for initiating resmetirom should not be raised compared with other groups; if anything, the higher baseline fibrosis burden in this population strengthens the case for earlier intervention [6].